Snap: Analysts Call For Company To Hit Guidance For Q1

Snap Inc (NYSE: SNAP) will be reporting their first quarter on April 22nd after market close. Analysts have a consensus $74.76 12-month price target on the company, via a total of 39 analysts, with nine analysts having strong buy ratings. 21 analysts meanwhile have buy ratings, eight have hold ratings and one analyst has a strong sell rating. The street high comes from Rosenblatt with a $100 price target, and the lowest target sits at $40.

31 analysts have revenue estimates for the first quarter. The company has also guided for revenues of between $720 and $740 million. The mean revenue estimate between all 31 analysts is $742.7 million; this number has been revised upwards from $692.5 million at the start of the year. The highest revenue estimate is $777.4 million, while the lowest is $728 million.

Onto EBITDA estimates, there are currently 28 analysts who have first-quarter EBITDA estimates. The company guided for negative $50 – $70 million for this quarter. The mean is currently negative $53.4 million, with this number having been revised down from a positive $14 million at the start of the year. Street high is a negative $3 million EBITDA estimate and the lowest being negative $90.1 million.

Analysts estimate that quarterly earnings per share will come in at negative $0.06, with this number being slightly revised down from negative $0.02 at the start of the year. Street high is negative $0.03 and the lowest estimate is negative $0.08 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Cambria Gold To Spin Out Mt. Margaret Copper-Gold Project Into US-Focused Entity

Two Vessels Attacked Near Strait of Hormuz Within Hours as IRGC Escalates Maritime Campaign

Related News

Xebec: Canaccord Views Three Year Plan As Ambitious, Without Risk

After an uneventful and lackluster quarter, Xebec Adsorption (TSX: XBC) provided investors with a three-year...

Friday, April 1, 2022, 03:43:00 PM

Canaccord: Alamos Gold’s Fourth Quarter Results Are “A Home Run”

Last week Alamos Gold (TSX: AGI) reported their fourth quarter and year end financial results...

Monday, March 1, 2021, 11:44:00 AM

Imperial Helium: Eight Capital Initiates Coverage With $1.00 Price Target

Imperial Helium (TSXV: IHC) had their first investment bank initiate coverage on them this past...

Saturday, June 5, 2021, 01:26:00 PM

Canaccord Downgrades Alimentation Couche-Tard Ahead Of Q4 Results

Ahead of Alimentation Couche-Tard’s (TSX: ATD.B) fiscal fourth-quarter results, Canaccord Genuity has downgraded the company...

Tuesday, June 22, 2021, 11:36:00 AM

Ayr Strategies: Canaccord Raises Price Target To $45

This morning Canaccord upgraded Ayr Strategies’ (CSE: AYR.A) twelve month price target to C$45 from...

Friday, December 11, 2020, 11:53:00 AM